Terms: = Endocrine gland cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b
142 results:
1. Myofibroblastic cancer-associated fibroblast subtype heterogeneity in pancreatic cancer.
Kearney JF; Trembath HE; Chan PS; Morrison AB; Xu Y; Luan CF; McCabe IC; Zarmer SA; Kim HJ; Peng XL; Yeh JJ
J Surg Oncol; 2024 Apr; 129(5):860-868. PubMed ID: 38233984
[TBL] [Abstract] [Full Text] [Related]
2. Suppressive stroma-immune prognostic signature impedes immunotherapy in ovarian cancer and can be reversed by pdgfrb inhibitors.
Yang D; Duan MH; Yuan QE; Li ZL; Luo CH; Cui LY; Li LC; Xiao Y; Zhu XY; Zhang HL; Feng GK; Liu GC; Deng R; Li JD; Zhu XF
J Transl Med; 2023 Sep; 21(1):586. PubMed ID: 37658364
[TBL] [Abstract] [Full Text] [Related]
3. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic Thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C
Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127
[No Abstract] [Full Text] [Related]
4. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
5. cancer-associated fibroblasts in papillary thyroid carcinoma.
Zhu L; Zhang X; Zhang S; Zhang Q; Cao L; Zhang Y; Wang D; Liang X; Wu W; Wu S; Jiang R; Liu Y; Zhao X; Zhou G; Xu K; Meng Z
Clin Exp Med; 2023 Oct; 23(6):2209-2220. PubMed ID: 36715834
[TBL] [Abstract] [Full Text] [Related]
6. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
van Eijck CWF; de Koning W; van der Sijde F; Moskie M; Groot Koerkamp B; Homs MYV; van der Burg SH; van Eijck CHJ; Mustafa DAM
Eur J Cancer; 2023 Mar; 181():119-134. PubMed ID: 36652890
[TBL] [Abstract] [Full Text] [Related]
7. Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer.
Shi YH; Xu QC; Zhu YQ; Liu ZD; Zhao GY; Liu Q; Wang XY; Wang JQ; Xu X; Su Q; Lai JM; Huang CS; Yin XY
Mol Ther; 2023 Feb; 31(2):503-516. PubMed ID: 36384875
[TBL] [Abstract] [Full Text] [Related]
8. Pancreatic ductal adenocarcinoma cells regulated the gemcitabine-resistance function of CAFs by LINC00460.
Zhu XX; Li JH; Ni X; Wu X; Hou X; Li YX; Li SJ; Zhao W; Yin XY
Cancer Sci; 2022 Nov; 113(11):3735-3750. PubMed ID: 36047966
[TBL] [Abstract] [Full Text] [Related]
9. Adrenal Cortical Carcinoma and Additional Rare Pathologic Findings in Multi-Organs in a Birt-Hogg-Dubé Syndrome Patient: With an Emphasis on the Molecular Characteristics of Adrenal Cortical Carcinoma.
Kim D; Murvelashvili N; Hamidi O; Jia L
Int J Surg Pathol; 2023 Aug; 31(5):689-694. PubMed ID: 35946080
[TBL] [Abstract] [Full Text] [Related]
10. Tumor Microenvironment-Associated Pericyte Populations May Impact Therapeutic Response in Thyroid cancer.
Iesato A; Nucera C
Adv Exp Med Biol; 2021; 1329():253-269. PubMed ID: 34664244
[TBL] [Abstract] [Full Text] [Related]
11. Lenvatinib Targets pdgfr-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights.
Iesato A; Li S; Roti G; Hacker MR; Fischer AH; Nucera C
J Clin Endocrinol Metab; 2021 Nov; 106(12):3569-3590. PubMed ID: 34302727
[TBL] [Abstract] [Full Text] [Related]
12. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.
Liang J; Jin Z; Kuang J; Feng H; Zhao Q; Yang Z; Zhan L; Shen B; Yan J; Cai W; Cheng X; Qiu W
Br J Cancer; 2021 Aug; 125(3):390-401. PubMed ID: 34088989
[TBL] [Abstract] [Full Text] [Related]
13. Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Li D; Chi Y; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Zheng X; Tang P; Gao M
Clin Cancer Res; 2021 Jul; 27(13):3567-3575. PubMed ID: 33832949
[TBL] [Abstract] [Full Text] [Related]
14. TMEM119 facilitates ovarian cancer cell proliferation, invasion, and migration via the pdgfrb/PI3K/AKT signaling pathway.
Sun T; Bi F; Liu Z; Yang Q
J Transl Med; 2021 Mar; 19(1):111. PubMed ID: 33731124
[TBL] [Abstract] [Full Text] [Related]
15. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
Abe I; Lam AK
Curr Oncol Rep; 2021 Feb; 23(3):31. PubMed ID: 33582932
[TBL] [Abstract] [Full Text] [Related]
16. Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment.
Lee JM; Annunziata CM; Hays JL; Cao L; Choyke P; Yu M; An D; Turkbey IB; Minasian LM; Steinberg SM; Chen H; Wright J; Kohn EC
Gynecol Oncol; 2020 Oct; 159(1):88-94. PubMed ID: 32747013
[TBL] [Abstract] [Full Text] [Related]
17. Tyrosine kinase inhibitor therapy and metabolic remodelling in papillary thyroid cancer.
Wagner M; Wuest M; Lopez-Campistrous A; Glubrecht D; Dufour J; Jans HS; Wuest F; McMullen TPW
Endocr Relat Cancer; 2020 Sep; 27(9):495-507. PubMed ID: 32590338
[TBL] [Abstract] [Full Text] [Related]
18. A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Duska LR; Petroni GR; Varhegyi N; Brown J; Jelovac D; Moore KN; McGuire WP; Darus C; Barroilhet LM; Secord AA
Gynecol Oncol; 2020 Jun; 157(3):585-592. PubMed ID: 32247603
[TBL] [Abstract] [Full Text] [Related]
19. Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of pdgfr expression.
Berndsen RH; Castrogiovanni C; Weiss A; Rausch M; Dallinga MG; Miljkovic-Licina M; Klaassen I; Meraldi P; van Beijnum JR; Nowak-Sliwinska P
Br J Cancer; 2019 Jul; 121(2):139-149. PubMed ID: 31235865
[TBL] [Abstract] [Full Text] [Related]
20. Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts.
Liu Y; Chanana P; Davila JI; Hou X; Zanfagnin V; McGehee CD; Goode EL; Polley EC; Haluska P; Weroha SJ; Wang C
Sci Rep; 2019 Apr; 9(1):6314. PubMed ID: 31004097
[TBL] [Abstract] [Full Text] [Related]
[Next]
